Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study, of the Safety and Efficacy of NG101 Administered Orally to Patients With Gastroparesis

NCT04303195 is registered in ClinicalTrials.gov with Neurogastrx, Inc. as lead sponsor.

NCT NCT04303195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04303195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study, of the Safety and Efficacy of NG101 Administered Orally to Patients With Gastroparesis
Lead sponsor
Neurogastrx, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 1, 2020
Completion date
February 25, 2023
Enrollment
161 (actual)
Sites
83

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic gastroparesis, idiopathic gastroparesis